The evolution of systemic therapy in sarcoma

Anastasia Constantinidou, Seth Pollack, Elizabeth Loggers, Eve Rodler, Robin L. Jones

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Approximately 50% of patients with localized soft tissue sarcomas will develop recurrent disease after complete surgical resection, requiring alternative means of treatment. Conventional chemotherapy comprising of doxorubicin and ifosfamide has shown benefit in advanced disease, however, there remains a clear need for more effective, less toxic, therapies for the treatment of this heterogeneous group of mesenchymal malignancies. Recently, greater emphasis has been placed on the underlying biology of individual sarcoma subtypes, with the development and evaluation of novel therapies both in common and in rare subtypes. In addition, there is a greater specificity in the selection of chemotherapy agents based on activity in individual histological subtypes. Despite these advances the management of sarcoma, and in particular of rare subtypes, remains a major challenge. Some histological subtypes are resistant to conventional chemotherapy and patients with these diseases should be offered participation in early phase clinical trials of novel drugs.

Original languageEnglish (US)
Pages (from-to)211-223
Number of pages13
JournalExpert Review of Anticancer Therapy
Volume13
Issue number2
DOIs
StatePublished - Feb 2013
Externally publishedYes

Fingerprint

Sarcoma
Drug Therapy
Ifosfamide
Poisons
Therapeutics
Doxorubicin
Clinical Trials
Pharmaceutical Preparations
Neoplasms

Keywords

  • angiogenesis
  • gemcitabine/docetaxel
  • pazopanib
  • rare histological subtype
  • sarcoma
  • systemic therapy
  • trabectedin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Constantinidou, A., Pollack, S., Loggers, E., Rodler, E., & Jones, R. L. (2013). The evolution of systemic therapy in sarcoma. Expert Review of Anticancer Therapy, 13(2), 211-223. https://doi.org/10.1586/era.12.161

The evolution of systemic therapy in sarcoma. / Constantinidou, Anastasia; Pollack, Seth; Loggers, Elizabeth; Rodler, Eve; Jones, Robin L.

In: Expert Review of Anticancer Therapy, Vol. 13, No. 2, 02.2013, p. 211-223.

Research output: Contribution to journalArticle

Constantinidou, A, Pollack, S, Loggers, E, Rodler, E & Jones, RL 2013, 'The evolution of systemic therapy in sarcoma', Expert Review of Anticancer Therapy, vol. 13, no. 2, pp. 211-223. https://doi.org/10.1586/era.12.161
Constantinidou, Anastasia ; Pollack, Seth ; Loggers, Elizabeth ; Rodler, Eve ; Jones, Robin L. / The evolution of systemic therapy in sarcoma. In: Expert Review of Anticancer Therapy. 2013 ; Vol. 13, No. 2. pp. 211-223.
@article{8c2e5b661df44ffca805e34cda196242,
title = "The evolution of systemic therapy in sarcoma",
abstract = "Approximately 50{\%} of patients with localized soft tissue sarcomas will develop recurrent disease after complete surgical resection, requiring alternative means of treatment. Conventional chemotherapy comprising of doxorubicin and ifosfamide has shown benefit in advanced disease, however, there remains a clear need for more effective, less toxic, therapies for the treatment of this heterogeneous group of mesenchymal malignancies. Recently, greater emphasis has been placed on the underlying biology of individual sarcoma subtypes, with the development and evaluation of novel therapies both in common and in rare subtypes. In addition, there is a greater specificity in the selection of chemotherapy agents based on activity in individual histological subtypes. Despite these advances the management of sarcoma, and in particular of rare subtypes, remains a major challenge. Some histological subtypes are resistant to conventional chemotherapy and patients with these diseases should be offered participation in early phase clinical trials of novel drugs.",
keywords = "angiogenesis, gemcitabine/docetaxel, pazopanib, rare histological subtype, sarcoma, systemic therapy, trabectedin",
author = "Anastasia Constantinidou and Seth Pollack and Elizabeth Loggers and Eve Rodler and Jones, {Robin L.}",
year = "2013",
month = "2",
doi = "10.1586/era.12.161",
language = "English (US)",
volume = "13",
pages = "211--223",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - The evolution of systemic therapy in sarcoma

AU - Constantinidou, Anastasia

AU - Pollack, Seth

AU - Loggers, Elizabeth

AU - Rodler, Eve

AU - Jones, Robin L.

PY - 2013/2

Y1 - 2013/2

N2 - Approximately 50% of patients with localized soft tissue sarcomas will develop recurrent disease after complete surgical resection, requiring alternative means of treatment. Conventional chemotherapy comprising of doxorubicin and ifosfamide has shown benefit in advanced disease, however, there remains a clear need for more effective, less toxic, therapies for the treatment of this heterogeneous group of mesenchymal malignancies. Recently, greater emphasis has been placed on the underlying biology of individual sarcoma subtypes, with the development and evaluation of novel therapies both in common and in rare subtypes. In addition, there is a greater specificity in the selection of chemotherapy agents based on activity in individual histological subtypes. Despite these advances the management of sarcoma, and in particular of rare subtypes, remains a major challenge. Some histological subtypes are resistant to conventional chemotherapy and patients with these diseases should be offered participation in early phase clinical trials of novel drugs.

AB - Approximately 50% of patients with localized soft tissue sarcomas will develop recurrent disease after complete surgical resection, requiring alternative means of treatment. Conventional chemotherapy comprising of doxorubicin and ifosfamide has shown benefit in advanced disease, however, there remains a clear need for more effective, less toxic, therapies for the treatment of this heterogeneous group of mesenchymal malignancies. Recently, greater emphasis has been placed on the underlying biology of individual sarcoma subtypes, with the development and evaluation of novel therapies both in common and in rare subtypes. In addition, there is a greater specificity in the selection of chemotherapy agents based on activity in individual histological subtypes. Despite these advances the management of sarcoma, and in particular of rare subtypes, remains a major challenge. Some histological subtypes are resistant to conventional chemotherapy and patients with these diseases should be offered participation in early phase clinical trials of novel drugs.

KW - angiogenesis

KW - gemcitabine/docetaxel

KW - pazopanib

KW - rare histological subtype

KW - sarcoma

KW - systemic therapy

KW - trabectedin

UR - http://www.scopus.com/inward/record.url?scp=84873926745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873926745&partnerID=8YFLogxK

U2 - 10.1586/era.12.161

DO - 10.1586/era.12.161

M3 - Article

C2 - 23406562

AN - SCOPUS:84873926745

VL - 13

SP - 211

EP - 223

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 2

ER -